Could a less frequent dose of a withdrawn myeloma drug bring new hope?
Disease control
Not yet recruiting
This study tests whether giving belantamab mafodotin every 6 weeks instead of every 3 weeks is safer and still works for people with advanced multiple myeloma that has not responded to other treatments. The drug was previously pulled from the market after a confirmatory study fai…
Phase: PHASE2 • Sponsor: Cristiana Costa Chase, DO • Aim: Disease control
Last updated May 04, 2026 16:19 UTC